首页 > 最新文献

Clinical and Experimental Vaccine Research最新文献

英文 中文
Factors associated with intention to take COVID-19 vaccine among the university students in Bangladesh. 孟加拉国大学生接种COVID-19疫苗意向的相关因素
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-09-01 DOI: 10.7774/cevr.2022.11.3.274
Nasir Ahmed Shuvo, Md Sanaul Haque Mondal

Purpose: This study examined the Bangladeshi university students' intention to take coronavirus disease 2019 (COVID-19) vaccines by assessing the Health Belief Model and Theory of Planned Behavior.

Materials and methods: University students were queried on their intention to take COVID-19 vaccines. The sample used in this study (n=310) was obtained through an online survey among university students (age, 18-25 years old) from August 7 to September 18, 2021.

Results: Although over 90% of respondents showed their willingness to take the COVID-19 vaccine, around 37.3% of respondents still desired to wait and see to take the vaccine. The most frequently cited reasons for vaccines hesitancy were concerns over side effects (62.4%). There is still an unmet need for adequate information on COVID-19 vaccines (81.4%). Results of the binary logistic regression model showed that students from private universities (odds ratio [OR], 0.19; 95% confidence interval [CI], 0.04-0.97), respondents who concerned about the vaccine safety (OR, 0.07; 95% CI, 0.01-0.44) and side effects of vaccine (OR, 0.21; 95% CI, 0.05-0.89) were less willing to take COVID-19 vaccine. On the other hand, desire to wait to take COVID-19 vaccines was associated with marital status (OR, 7.76; 95% CI, 1.50-40.27); COVID-19 preventive behavior, including use of facemask (OR, 0.25; 95% CI, 0.09-0.70) and maintain social distance (OR,1.75; 95% CI, 1.00-3.07); COVID-19 infection (OR, 0.50; 95% CI, 0.26-0.99); provide more information on vaccines (OR, 2.32; 95% CI, 1.06-5.09); the perceived side effects (OR, 2.82; 95% CI, 1.54-5.17); and effectiveness of COVID-19 vaccines (OR, 2.41; 95% CI, 1.16-5.01).

Conclusion: Public health managers should provide adequate information on COVID-19 vaccines to address the concerns about the safety and side effects of the vaccines.

目的:本研究通过评估健康信念模型和计划行为理论,考察孟加拉国大学生接种2019冠状病毒病(COVID-19)疫苗的意愿。材料与方法:对大学生接种新冠肺炎疫苗意向进行问卷调查。本研究使用的样本(n=310)是在2021年8月7日至9月18日对18-25岁的大学生进行在线调查获得的。结果:虽然超过90%的受访者表示愿意接种新冠肺炎疫苗,但约37.3%的受访者仍希望观望接种疫苗。对疫苗犹豫最常见的原因是担心副作用(62.4%)。对COVID-19疫苗充分信息的需求仍未得到满足(81.4%)。二元logistic回归模型结果显示,私立大学学生(优势比[OR], 0.19;95%可信区间[CI], 0.04-0.97),关注疫苗安全性的应答者(OR, 0.07;95% CI, 0.01-0.44)和疫苗副作用(OR, 0.21;95% CI, 0.05-0.89)不太愿意接种COVID-19疫苗。另一方面,等待接种COVID-19疫苗的意愿与婚姻状况相关(OR, 7.76;95% ci, 1.50-40.27);COVID-19预防行为,包括使用口罩(OR, 0.25;95% CI, 0.09-0.70)并保持社会距离(OR,1.75;95% ci, 1.00-3.07);COVID-19感染(OR, 0.50;95% ci, 0.26-0.99);提供更多关于疫苗的信息(OR, 2.32;95% ci, 1.06-5.09);感知到的副作用(OR, 2.82;95% ci, 1.54-5.17);COVID-19疫苗的有效性(OR, 2.41;95% ci, 1.16-5.01)。结论:公共卫生管理者应提供足够的COVID-19疫苗信息,以解决对疫苗安全性和副作用的担忧。
{"title":"Factors associated with intention to take COVID-19 vaccine among the university students in Bangladesh.","authors":"Nasir Ahmed Shuvo,&nbsp;Md Sanaul Haque Mondal","doi":"10.7774/cevr.2022.11.3.274","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.3.274","url":null,"abstract":"<p><strong>Purpose: </strong>This study examined the Bangladeshi university students' intention to take coronavirus disease 2019 (COVID-19) vaccines by assessing the Health Belief Model and Theory of Planned Behavior.</p><p><strong>Materials and methods: </strong>University students were queried on their intention to take COVID-19 vaccines. The sample used in this study (n=310) was obtained through an online survey among university students (age, 18-25 years old) from August 7 to September 18, 2021.</p><p><strong>Results: </strong>Although over 90% of respondents showed their willingness to take the COVID-19 vaccine, around 37.3% of respondents still desired to wait and see to take the vaccine. The most frequently cited reasons for vaccines hesitancy were concerns over side effects (62.4%). There is still an unmet need for adequate information on COVID-19 vaccines (81.4%). Results of the binary logistic regression model showed that students from private universities (odds ratio [OR], 0.19; 95% confidence interval [CI], 0.04-0.97), respondents who concerned about the vaccine safety (OR, 0.07; 95% CI, 0.01-0.44) and side effects of vaccine (OR, 0.21; 95% CI, 0.05-0.89) were less willing to take COVID-19 vaccine. On the other hand, desire to wait to take COVID-19 vaccines was associated with marital status (OR, 7.76; 95% CI, 1.50-40.27); COVID-19 preventive behavior, including use of facemask (OR, 0.25; 95% CI, 0.09-0.70) and maintain social distance (OR,1.75; 95% CI, 1.00-3.07); COVID-19 infection (OR, 0.50; 95% CI, 0.26-0.99); provide more information on vaccines (OR, 2.32; 95% CI, 1.06-5.09); the perceived side effects (OR, 2.82; 95% CI, 1.54-5.17); and effectiveness of COVID-19 vaccines (OR, 2.41; 95% CI, 1.16-5.01).</p><p><strong>Conclusion: </strong>Public health managers should provide adequate information on COVID-19 vaccines to address the concerns about the safety and side effects of the vaccines.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 3","pages":"274-284"},"PeriodicalIF":2.7,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/34/cevr-11-274.PMC9691862.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10389165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
COVID-19 vaccines development in Africa: a review of current situation and existing challenges of vaccine production. 非洲 COVID-19 疫苗开发:疫苗生产现状和现有挑战回顾。
IF 2.1 Q4 IMMUNOLOGY Pub Date : 2022-09-01 Epub Date: 2022-09-30 DOI: 10.7774/cevr.2022.11.3.302
Olawale Adeyemi
{"title":"COVID-19 vaccines development in Africa: a review of current situation and existing challenges of vaccine production.","authors":"Olawale Adeyemi","doi":"10.7774/cevr.2022.11.3.302","DOIUrl":"10.7774/cevr.2022.11.3.302","url":null,"abstract":"","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 3","pages":"302-303"},"PeriodicalIF":2.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4e/3d/cevr-11-302.PMC9691864.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10678642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the myths surrounding the COVID-19 vaccines in Africa: the study to investigate their impacts on acceptance using online survey and social media. 探索非洲COVID-19疫苗的神话:利用在线调查和社交媒体调查其对接受度的影响的研究。
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-05-01 DOI: 10.7774/cevr.2022.11.2.193
Emmanuel Lamptey, Ephraim Kumi Senkyire, Serwaa Dorcas, Dooshima Aki Benita, Evans Osei Boakye, Theckla Ikome, Alex Asamoah

Purpose: The coronavirus disease 2019 (COVID-19) vaccine is the key to getting out of the pandemic. However, acceptance of the vaccine has been affected by false information and rumors, which have kept people from getting the shot since it was rolled out.

Materials and methods: This study aimed to investigate the various misconceptions surfaced about the COVID-19 vaccines in Africa. We performed an online survey using an anonymous questionnaire to reach out to African respondents by social media and all possible online platforms such as Facebook, WhatsApp, Instagram, Twitter, YouTube, and so forth. The web-based questionnaires about the myths surrounding the vaccines were extracted from nonscientific information, unproven statements, social media posts, news reports, and people's concerns about the safety of the COVID-19 vaccines. Participants indicated their level of agreement with each statement.

Results: A total of 2,500 people responded to the online survey in Africa. The two common myths that respondents agreed with were that "since vaccines for COVID-19 have been developed, we can make vaccines for the common cold, human immunodeficiency viruses, and other diseases" (n=892, 35.7%) and that "researchers rushed the development of the COVID-19 vaccines; therefore, it is not very effective, safe and cannot be trusted" (n=595, 23.8%). The range of respondents who neither agreed nor disagreed with these myths was 12.4%-33.0%. The majority (1,931, 77.2%) indicated disagreement with the statement "after getting the COVID-19 vaccine, one can stop wearing a mask as well as taking safety precautions."

Conclusion: Myths surrounding the COVID-19 vaccines have impact on acceptance. Exploring them helps public health authorities in Africa dispel them and provide accurate information to promote vaccination campaigns, education, and acceptance.

目的:2019冠状病毒病(COVID-19)疫苗是摆脱疫情的关键。然而,自疫苗推出以来,人们对疫苗的接受程度受到虚假信息和谣言的影响,这些信息和谣言使人们无法接种疫苗。材料和方法:本研究旨在调查非洲对COVID-19疫苗的各种误解。我们进行了一项在线调查,使用匿名问卷,通过社交媒体和所有可能的在线平台,如Facebook、WhatsApp、Instagram、Twitter、YouTube等,接触到非洲的受访者。基于网络的关于疫苗神话的调查问卷是从非科学信息、未经证实的陈述、社交媒体帖子、新闻报道以及人们对COVID-19疫苗安全性的担忧中提取的。参与者表明了他们对每个陈述的同意程度。结果:共有2500人对非洲的在线调查做出了回应。受访者认同的两个常见误区是“既然已经开发出了COVID-19疫苗,我们就可以生产普通感冒、人类免疫缺陷病毒和其他疾病的疫苗”(n=892, 35.7%)和“研究人员匆忙开发了COVID-19疫苗;因此,它不是很有效,不安全,不能信任”(n=595, 23.8%)。12.4%-33.0%的受访者既不同意也不反对这些说法。大多数人(1931人,77.2%)不同意“接种新冠病毒疫苗后,可以不戴口罩,也可以采取安全措施”的说法。结论:围绕COVID-19疫苗的误解影响了人们的接受程度。探索这些问题有助于非洲的公共卫生当局消除它们,并提供准确的信息,以促进疫苗接种运动、教育和接受。
{"title":"Exploring the myths surrounding the COVID-19 vaccines in Africa: the study to investigate their impacts on acceptance using online survey and social media.","authors":"Emmanuel Lamptey,&nbsp;Ephraim Kumi Senkyire,&nbsp;Serwaa Dorcas,&nbsp;Dooshima Aki Benita,&nbsp;Evans Osei Boakye,&nbsp;Theckla Ikome,&nbsp;Alex Asamoah","doi":"10.7774/cevr.2022.11.2.193","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.2.193","url":null,"abstract":"<p><strong>Purpose: </strong>The coronavirus disease 2019 (COVID-19) vaccine is the key to getting out of the pandemic. However, acceptance of the vaccine has been affected by false information and rumors, which have kept people from getting the shot since it was rolled out.</p><p><strong>Materials and methods: </strong>This study aimed to investigate the various misconceptions surfaced about the COVID-19 vaccines in Africa. We performed an online survey using an anonymous questionnaire to reach out to African respondents by social media and all possible online platforms such as Facebook, WhatsApp, Instagram, Twitter, YouTube, and so forth. The web-based questionnaires about the myths surrounding the vaccines were extracted from nonscientific information, unproven statements, social media posts, news reports, and people's concerns about the safety of the COVID-19 vaccines. Participants indicated their level of agreement with each statement.</p><p><strong>Results: </strong>A total of 2,500 people responded to the online survey in Africa. The two common myths that respondents agreed with were that \"since vaccines for COVID-19 have been developed, we can make vaccines for the common cold, human immunodeficiency viruses, and other diseases\" (n=892, 35.7%) and that \"researchers rushed the development of the COVID-19 vaccines; therefore, it is not very effective, safe and cannot be trusted\" (n=595, 23.8%). The range of respondents who neither agreed nor disagreed with these myths was 12.4%-33.0%. The majority (1,931, 77.2%) indicated disagreement with the statement \"after getting the COVID-19 vaccine, one can stop wearing a mask as well as taking safety precautions.\"</p><p><strong>Conclusion: </strong>Myths surrounding the COVID-19 vaccines have impact on acceptance. Exploring them helps public health authorities in Africa dispel them and provide accurate information to promote vaccination campaigns, education, and acceptance.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 2","pages":"193-208"},"PeriodicalIF":2.7,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ec/9f/cevr-11-193.PMC9200652.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10491293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Thalamic hemi-chorea: a rare complication after receiving the adenoviral vector-based COVID-19 vaccine: a case report. 丘脑半舞蹈病:接种基于腺病毒载体的COVID-19疫苗后的罕见并发症:1例报告
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-05-01 DOI: 10.7774/cevr.2022.11.2.217
Hamze Shahali, Ramin Hamidi Farahani, Ali Asgari, Ebrahim Hazrati

Lacunar strokes occur when a branch of a large cerebral artery is blocked. The thalamus is often affected, causing uncontrollable motions. A 72-year-old previously healthy man presented with involuntary motions in the right limbs, which were present at rest, and exacerbated during voluntary actions. He had received the first dose of the adenoviral vector-based coronavirus disease 2019 vaccine (ChAdOx1 nCoV-19) 9 days ago. Severe thrombocytopenia and elevated levels of lactate dehydrogenase, ferritin, C-reactive protein, and D-dimer were found, without any evidence of connective tissue disease. Electromyography demonstrated typical choreiform movements, and the brain magnetic resonance imaging indicated a small high signal lesion on the left side of the thalamus. Detection of the immunoglobulin G antibodies against platelet factor 4 in the blood, negative heparin-induced platelet activation (HIPA) test, and positive modified HIPA test confirmed the thalamic stroke due to the vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). He was admitted to the intensive care unit and received nadroparin, sodium ozagrel, edaravone, methylprednisolone, and haloperidol. His hemi-chorea improved gradually over 2 weeks, and he was discharged after 21 days with rehabilitation advice. VIPIT due to the ChAdOx1 nCoV-19 is a novel immune-mediated response that needs clinicians' awareness and further investigations.

脑腔隙性中风发生在大脑大动脉的一个分支被阻塞的时候。丘脑经常受到影响,导致无法控制的运动。一名72岁以前健康的男性,在休息时出现右肢体不自主运动,并在自主活动时加重。9天前,他接种了第一剂基于腺病毒载体的2019冠状病毒病疫苗(ChAdOx1 nCoV-19)。发现严重的血小板减少症和乳酸脱氢酶、铁蛋白、c反应蛋白和d -二聚体水平升高,无结缔组织疾病的证据。肌电图显示典型的舞蹈样运动,脑磁共振成像显示丘脑左侧有一个小的高信号病变。血液中抗血小板因子4的免疫球蛋白G抗体检测、肝素诱导血小板活化(HIPA)试验阴性、改良HIPA试验阳性均证实疫苗诱导的血栓性免疫性血小板减少症(VIPIT)所致丘脑卒中。他被送进重症监护室,接受了nadroparin、ozagrel钠、依达拉奉、甲基强的松龙和氟哌啶醇。他的半舞蹈症在2周内逐渐改善,并在康复建议下于21天后出院。由ChAdOx1 nCoV-19引起的VIPIT是一种新的免疫介导反应,需要临床医生的认识和进一步的研究。
{"title":"Thalamic hemi-chorea: a rare complication after receiving the adenoviral vector-based COVID-19 vaccine: a case report.","authors":"Hamze Shahali,&nbsp;Ramin Hamidi Farahani,&nbsp;Ali Asgari,&nbsp;Ebrahim Hazrati","doi":"10.7774/cevr.2022.11.2.217","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.2.217","url":null,"abstract":"<p><p>Lacunar strokes occur when a branch of a large cerebral artery is blocked. The thalamus is often affected, causing uncontrollable motions. A 72-year-old previously healthy man presented with involuntary motions in the right limbs, which were present at rest, and exacerbated during voluntary actions. He had received the first dose of the adenoviral vector-based coronavirus disease 2019 vaccine (ChAdOx1 nCoV-19) 9 days ago. Severe thrombocytopenia and elevated levels of lactate dehydrogenase, ferritin, C-reactive protein, and D-dimer were found, without any evidence of connective tissue disease. Electromyography demonstrated typical choreiform movements, and the brain magnetic resonance imaging indicated a small high signal lesion on the left side of the thalamus. Detection of the immunoglobulin G antibodies against platelet factor 4 in the blood, negative heparin-induced platelet activation (HIPA) test, and positive modified HIPA test confirmed the thalamic stroke due to the vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). He was admitted to the intensive care unit and received nadroparin, sodium ozagrel, edaravone, methylprednisolone, and haloperidol. His hemi-chorea improved gradually over 2 weeks, and he was discharged after 21 days with rehabilitation advice. VIPIT due to the ChAdOx1 nCoV-19 is a novel immune-mediated response that needs clinicians' awareness and further investigations.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 2","pages":"217-221"},"PeriodicalIF":2.7,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/16/cevr-11-217.PMC9200646.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10775563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Protection against virulent Brucella spp. by gamma-irradiated B. ovis in BALB/c mice model γ辐照对BALB/c小鼠模型中布鲁氏菌的保护作用
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.53
A. Al-Mariri, Laila Al-Hallab, Rasha Alabras, Heba Kherbik, Marwa Khawajkiah
Purpose Brucella spp. is a zoonosis that causes undulant fever in humans and abortion in livestock worldwide. Lately, it was conveyed that vaccines developed by irradiation have induced a strong cellular and humoral immune response which have made these types of vaccines highly effective. Materials and Methods In this study, we aimed to use the gamma-irradiated B. ovis as a vaccine and to study the humoral immune response and cytokines production in order to evaluate it for protecting mice against B. abortus 544, B. melitensis 16M, and B. ovis. Results The humoral immune response in immunized mice with gamma-irradiated B. ovis showed a lasting for 8 weeks after immunization. Moreover, immunoglobulin G (IgG), IgG1, IgG2a, and IgG2b isotypes antibodies against B. ovis were observed after 4 and 8 weeks of the last immunization. It was noticed that the production of tumor necrosis factor-α, interferon-γ, and interleukin (IL)-10 continued after 4 and 8 weeks by splenocytes from immunized BALB/c mice, while no production of IL-4 or IL-5 was observed. Conclusion Our results indicate that the protection of BALB/c mice against B. melitensis 16M, B. abortus 544, and B. ovis was induced and the developed vaccine at our laboratory could stimulate similar protection to those induced by the traditional vaccine.
目的布鲁氏菌是一种人畜共患病,在世界范围内引起人类波动热和牲畜流产。最近,有人表示,通过辐照研制的疫苗已引起强烈的细胞和体液免疫反应,使这类疫苗非常有效。材料与方法本研究以γ辐照的b - ovis为疫苗,研究其对abortus 544、b - melitensis 16M和b - ovis的保护作用,并研究其体液免疫反应和细胞因子的产生。结果γ辐照后免疫小鼠的体液免疫反应持续8周。在末次免疫4周和8周后,检测到免疫球蛋白G (IgG)、IgG1、IgG2a和IgG2b同型抗体。我们注意到免疫BALB/c小鼠的脾细胞在4周和8周后继续产生肿瘤坏死因子-α、干扰素-γ和白细胞介素(IL)-10,而未观察到IL-4或IL-5的产生。结论BALB/c小鼠对melitensis 16M、B. abortus 544和B. ovis具有诱导保护作用,且本实验室研制的疫苗具有与传统疫苗相似的保护作用。
{"title":"Protection against virulent Brucella spp. by gamma-irradiated B. ovis in BALB/c mice model","authors":"A. Al-Mariri, Laila Al-Hallab, Rasha Alabras, Heba Kherbik, Marwa Khawajkiah","doi":"10.7774/cevr.2022.11.1.53","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.53","url":null,"abstract":"Purpose Brucella spp. is a zoonosis that causes undulant fever in humans and abortion in livestock worldwide. Lately, it was conveyed that vaccines developed by irradiation have induced a strong cellular and humoral immune response which have made these types of vaccines highly effective. Materials and Methods In this study, we aimed to use the gamma-irradiated B. ovis as a vaccine and to study the humoral immune response and cytokines production in order to evaluate it for protecting mice against B. abortus 544, B. melitensis 16M, and B. ovis. Results The humoral immune response in immunized mice with gamma-irradiated B. ovis showed a lasting for 8 weeks after immunization. Moreover, immunoglobulin G (IgG), IgG1, IgG2a, and IgG2b isotypes antibodies against B. ovis were observed after 4 and 8 weeks of the last immunization. It was noticed that the production of tumor necrosis factor-α, interferon-γ, and interleukin (IL)-10 continued after 4 and 8 weeks by splenocytes from immunized BALB/c mice, while no production of IL-4 or IL-5 was observed. Conclusion Our results indicate that the protection of BALB/c mice against B. melitensis 16M, B. abortus 544, and B. ovis was induced and the developed vaccine at our laboratory could stimulate similar protection to those induced by the traditional vaccine.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"53 - 62"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48490374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of full and fragment-B of diphtheria toxin genes in Escherichia coli for generating of recombinant diphtheria vaccines 白喉毒素全片段B基因在大肠杆菌中的表达及重组白喉疫苗的制备
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.12
Shaimaa Abulmagd, A. E. Khattab, H. Zedan
Purpose In the present study, whole diphtheria toxin (dt) and fragment B (dtb) genes from Corynebacterium diphtheriae Park William were cloned into Escherichia coli, the purified expressed proteins were evaluated for ultimately using as a candidate vaccine. Materials and Methods The dt and dtb genes were isolated from bacterial strain ATCC (American Type Culture Collection) no. 13812. Plasmid pET29a+ was extracted by DNA-spin TM plasmid purification kit where genes were inserted using BamHI and HindIII-HF. Cloned pET29a+dt and pET29a+dtb plasmids were transformed into E. coli BL21(DE3)PlysS as expression host. The identity of the sequences was validated by blasting the sequence (BLASTn) against all the reported nucleotide sequences in the NCBI (National Center for Biotechnology Information) GenBank. Production of proteins in high yield by different types and parameters of fermentation to determine optimal conditions. Lastly, the purified concentrated rdtx and rdtb were injected to BALB/c mice and antibody titers were detected. Results The genetic transformation of E. coli DH5α and E. coli BL21 with the pET-29a(+) carrying the dt and dtb genes was confirmed by colony polymerase chain reaction assay and were positive to grow on Luria-Bertani/kanamycin medium. The open reading frame of dt and dtb sequences consisted of 1,600 bp and 1,000 bp, were found to be 100% identical to dt and dtb sequence of C. diphtheriae (accession number KX702999.1 and KX702993.1) respectively. The optimal condition for high cell density is fed-batch fermentation production to express the rdtx and rdtb at 280 and 240 Lf/mL, dissolved oxygen was about 24% and 22% and the dry cell weight of bacteria was 2.41 g/L and 2.18 g/L, respectively. Conclusion This study concluded with success in preparing genetically modified two strains for the production of a diphtheria vaccine, and to reach ideal production conditions to achieve the highest productivity.
目的本研究将白喉棒状杆菌Park William的白喉毒素(dt)和B片段(dtb)基因克隆到大肠杆菌中,并对纯化的表达蛋白进行评价,最终用作候选疫苗。材料和方法从ATCC(American Type Culture Collection)13812菌株中分离出dt和dtb基因。质粒pET29a+通过DNA spin-TM质粒纯化试剂盒提取,其中使用BamHI和HindIII-HF插入基因。将克隆的pET29a+dt和pET29a+dtb质粒转化到大肠杆菌BL21(DE3)PlysS中作为表达宿主。通过对NCBI(国家生物技术信息中心)GenBank中所有报道的核苷酸序列爆破序列(BLASTn)来验证序列的同一性。通过不同类型和参数的发酵来确定高产蛋白质的最佳条件。最后,将纯化的浓缩rdtx和rdtb注射到BALB/c小鼠中,并检测抗体滴度。结果用携带dt和dtb基因的pET-29a(+)对大肠杆菌DH5α和大肠杆菌BL21进行了遗传转化,并在Luria Bertani/卡那霉素培养基上呈阳性生长。发现由1600bp和1000bp组成的dt和dtb序列的开放阅读框分别与白喉杆菌的dt和dtb序列(登录号KX702999.1和KX702993.1)100%相同。高细胞密度的最佳条件是补料分批发酵生产,以280和240Lf/mL表达rdtx和rdtb,溶解氧约为24%和22%,细菌干细胞重量分别为2.41g/L和2.18g/L。结论本研究成功地制备了两株用于生产白喉疫苗的转基因菌株,并达到了理想的生产条件,达到了最高的生产效率。
{"title":"Expression of full and fragment-B of diphtheria toxin genes in Escherichia coli for generating of recombinant diphtheria vaccines","authors":"Shaimaa Abulmagd, A. E. Khattab, H. Zedan","doi":"10.7774/cevr.2022.11.1.12","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.12","url":null,"abstract":"Purpose In the present study, whole diphtheria toxin (dt) and fragment B (dtb) genes from Corynebacterium diphtheriae Park William were cloned into Escherichia coli, the purified expressed proteins were evaluated for ultimately using as a candidate vaccine. Materials and Methods The dt and dtb genes were isolated from bacterial strain ATCC (American Type Culture Collection) no. 13812. Plasmid pET29a+ was extracted by DNA-spin TM plasmid purification kit where genes were inserted using BamHI and HindIII-HF. Cloned pET29a+dt and pET29a+dtb plasmids were transformed into E. coli BL21(DE3)PlysS as expression host. The identity of the sequences was validated by blasting the sequence (BLASTn) against all the reported nucleotide sequences in the NCBI (National Center for Biotechnology Information) GenBank. Production of proteins in high yield by different types and parameters of fermentation to determine optimal conditions. Lastly, the purified concentrated rdtx and rdtb were injected to BALB/c mice and antibody titers were detected. Results The genetic transformation of E. coli DH5α and E. coli BL21 with the pET-29a(+) carrying the dt and dtb genes was confirmed by colony polymerase chain reaction assay and were positive to grow on Luria-Bertani/kanamycin medium. The open reading frame of dt and dtb sequences consisted of 1,600 bp and 1,000 bp, were found to be 100% identical to dt and dtb sequence of C. diphtheriae (accession number KX702999.1 and KX702993.1) respectively. The optimal condition for high cell density is fed-batch fermentation production to express the rdtx and rdtb at 280 and 240 Lf/mL, dissolved oxygen was about 24% and 22% and the dry cell weight of bacteria was 2.41 g/L and 2.18 g/L, respectively. Conclusion This study concluded with success in preparing genetically modified two strains for the production of a diphtheria vaccine, and to reach ideal production conditions to achieve the highest productivity.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"12 - 29"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47447762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Large inter-individual variability of cellular and humoral immunological responses to mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in health care workers. 医护人员对SARS-CoV-2 mRNA-1273 (Moderna)疫苗接种的细胞和体液免疫反应的大个体间差异
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 Epub Date: 2022-01-31 DOI: 10.7774/cevr.2022.11.1.96
Alexander Krüttgen, Gerhard Haase, Helga Haefner, Matthias Imöhl, Michael Kleines

Purpose: Studies on the immune responses to severe acute respiratory syndrome coronavirus 2 vaccines are necessary to evaluate the ongoing vaccination programs by correlating serological response data and clinical effectiveness data. We performed a longitudinal immunological profiling of health care workers vaccinated with mRNA-1273 (Moderna, Cambridge, MA, USA). Half of these vaccinees had experienced a mild coronavirus disease 2019 (COVID-19) infection in the spring of 2020 ("COVID-recovered" cohort), whereas the other half of the vaccinees had no previous COVID-19 infection ("COVID-naive" cohort).

Materials and methods: Serum was drawn at multiple time points and subjected to assays measuring anti-Spike immunoglobulin G (IgG), avidity of anti-Spike IgG, avidity of anti-receptor binding domain (RBD) IgG, virus neutralizing activity, and interferon-γ release from stimulated lymphocytes.

Results: Between both cohorts and within each cohort, we found remarkable inter-individual differences regarding cellular and humoral immune responses to the Moderna mRNA-1273 vaccine.

Conclusion: First, our study indicates that the success of mRNA-1273 vaccinations should be verified by serological assays in order to identify "low-responders" to vaccination. Second, the kinetics of anti-S IgG and neutralizing activity correlate well with clinical effectiveness data, thus explaining incipient protection against infection 2 weeks after the first dose of mRNA-1273 in COVID-naive vaccinees. Third, our IgG-avidity data indicate that this incipient protection is mediated by low-avidity anti-RBD IgG and low-avidity anti-S IgG.

目的研究严重急性呼吸综合征冠状病毒2型疫苗的免疫反应,有必要通过关联血清学反应数据和临床有效性数据来评估正在进行的疫苗接种计划。我们对接种mRNA-1273(Moderna,Cambridge,MA,USA)的医护人员进行了纵向免疫学分析。这些疫苗接种者中有一半在2020年春季经历了2019年轻度冠状病毒病(新冠肺炎)感染(“新冠肺炎覆盖”队列),而另一半疫苗接种者之前没有新冠肺炎感染(“COVID命名”队列)。材料和方法在多个时间点抽取血清,测定抗刺突免疫球蛋白G(IgG)、抗刺突IgG亲和力、抗受体结合域(RBD)IgG亲和力、病毒中和活性和刺激淋巴细胞释放干扰素-γ。结果在两个队列之间和每个队列中,我们发现对莫德纳mRNA-1273疫苗的细胞和体液免疫反应存在显著的个体间差异。结论首先,我们的研究表明,mRNA-1273疫苗接种的成功应该通过血清学检测来验证,以确定疫苗接种的“低应答者”。其次,抗S IgG和中和活性的动力学与临床有效性数据密切相关,从而解释了在新冠肺炎初始疫苗接种者中第一剂mRNA-1273后2周对感染的早期保护作用。第三,我们的IgG亲和力数据表明,这种早期保护是由低亲和力抗RBD IgG和低亲和力抗S IgG介导的。
{"title":"Large inter-individual variability of cellular and humoral immunological responses to mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in health care workers.","authors":"Alexander Krüttgen,&nbsp;Gerhard Haase,&nbsp;Helga Haefner,&nbsp;Matthias Imöhl,&nbsp;Michael Kleines","doi":"10.7774/cevr.2022.11.1.96","DOIUrl":"10.7774/cevr.2022.11.1.96","url":null,"abstract":"<p><strong>Purpose: </strong>Studies on the immune responses to severe acute respiratory syndrome coronavirus 2 vaccines are necessary to evaluate the ongoing vaccination programs by correlating serological response data and clinical effectiveness data. We performed a longitudinal immunological profiling of health care workers vaccinated with mRNA-1273 (Moderna, Cambridge, MA, USA). Half of these vaccinees had experienced a mild coronavirus disease 2019 (COVID-19) infection in the spring of 2020 (\"COVID-recovered\" cohort), whereas the other half of the vaccinees had no previous COVID-19 infection (\"COVID-naive\" cohort).</p><p><strong>Materials and methods: </strong>Serum was drawn at multiple time points and subjected to assays measuring anti-Spike immunoglobulin G (IgG), avidity of anti-Spike IgG, avidity of anti-receptor binding domain (RBD) IgG, virus neutralizing activity, and interferon-γ release from stimulated lymphocytes.</p><p><strong>Results: </strong>Between both cohorts and within each cohort, we found remarkable inter-individual differences regarding cellular and humoral immune responses to the Moderna mRNA-1273 vaccine.</p><p><strong>Conclusion: </strong>First, our study indicates that the success of mRNA-1273 vaccinations should be verified by serological assays in order to identify \"low-responders\" to vaccination. Second, the kinetics of anti-S IgG and neutralizing activity correlate well with clinical effectiveness data, thus explaining incipient protection against infection 2 weeks after the first dose of mRNA-1273 in COVID-naive vaccinees. Third, our IgG-avidity data indicate that this incipient protection is mediated by low-avidity anti-RBD IgG and low-avidity anti-S IgG.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"96-103"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44525660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Severity of adverse reactions is associated with T-cell response in mRNA-1273 vaccinated health care workers 不良反应的严重程度与接种mRNA-1273疫苗的卫生保健工作者的t细胞反应有关
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.121
Hanna Klingel, Maike Lauen, A. Krüttgen, M. Imöhl, M. Kleines
Knowledge about mRNA-1273 elicited T-cell response is limited. We investigated adverse reactions and interferon gamma release by specific T-cells among mRNA-1273 vaccinated health care workers. Seven to 13 weeks after complete vaccination low levels of specific T-cells were detected not correlating with antibody response. Severity of symptoms after first and number of symptoms after second immunization were associated with T-cell response. Assessment of T-cell response in addition to antibody response is crucial because even few specific T-cells could add to protection against infection. Investigation of mRNA-1273 induced inflammatory processes might help improve reactogenicity and immunogenicity.
关于mRNA-1273引发的T细胞反应的知识是有限的。我们调查了接种mRNA-1273疫苗的医护人员的不良反应和特异性T细胞释放干扰素γ的情况。在完全接种疫苗后7至13周,检测到低水平的特异性T细胞与抗体反应无关。第一次免疫后症状的严重程度和第二次免疫后的症状数量与T细胞反应有关。除了抗体反应外,评估T细胞反应也是至关重要的,因为即使是很少的特异性T细胞也可以增加对感染的保护。研究mRNA-1273诱导的炎症过程可能有助于提高反应原性和免疫原性。
{"title":"Severity of adverse reactions is associated with T-cell response in mRNA-1273 vaccinated health care workers","authors":"Hanna Klingel, Maike Lauen, A. Krüttgen, M. Imöhl, M. Kleines","doi":"10.7774/cevr.2022.11.1.121","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.121","url":null,"abstract":"Knowledge about mRNA-1273 elicited T-cell response is limited. We investigated adverse reactions and interferon gamma release by specific T-cells among mRNA-1273 vaccinated health care workers. Seven to 13 weeks after complete vaccination low levels of specific T-cells were detected not correlating with antibody response. Severity of symptoms after first and number of symptoms after second immunization were associated with T-cell response. Assessment of T-cell response in addition to antibody response is crucial because even few specific T-cells could add to protection against infection. Investigation of mRNA-1273 induced inflammatory processes might help improve reactogenicity and immunogenicity.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"121 - 124"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44645273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Reactogenicity to COVID-19 vaccination in the United States of America 美利坚合众国对新冠肺炎疫苗接种的反应原性
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.104
A. Sanyaolu, A. Marinkovic, S. Prakash, P. Desai, N. Haider, A. Abbasi, Nasima Mehraban, Isha Jain, Amarachi Ekeh, Omar Shazley, C. Okorie, V. Orish
Purpose In the United States, Pfizer-BioNTech, Moderna, and Janssen’s coronavirus disease 2019 (COVID-19) vaccines have been granted Emergency Use Authorization (EUA) with the Pfizer-BioNTech vaccine presently approved by the US Food and Drug Administration. The purpose of this study is to analyze passive surveillance data on COVID-19 vaccine adverse reaction in the United States. Materials and Methods We analyzed passive surveillance data on COVID-19 vaccine adverse reactions which were retrieved from the Vaccine Adverse Event Reporting System database. Retrieved records on demographic information as well as the top 10 common vaccine adverse events were extracted and assessed from 200 of the most recently reported cases for the study analysis. Results Local and systemic adverse reactions were reported in the study. A significant difference (p<0.05) was recorded for the top 10 systemic reactions by age category (0.041) and by gender (0.002). Analysis of the top five systemic reactions, stratified by vaccine type yielded a significant difference (p<0.05) for chills (p=0.044), and when stratified by age group and type of vaccination received, it yielded a significant difference (p<0.05) for fatigue (p=0.023). Overall, Pfizer had 182 persons (91.0%) reporting adverse events, Moderna with 13 (6.5%), and Janssen with 5 (2.5%). Conclusion Mild side effects were reported following vaccination with the EUA COVID-19 vaccines in the United States. Thus, continuous monitoring and reporting of all adverse events are recommended to ensure the safety of vaccination.
目的在美国,Pfizer-BioNTech、Moderna和Janssen的2019冠状病毒病(新冠肺炎)疫苗已获得紧急使用授权(EUA),目前已获得美国食品和药物管理局批准的PfizerBioNTech疫苗。本研究的目的是分析美国新冠肺炎疫苗不良反应的被动监测数据。材料和方法我们分析了从疫苗不良事件报告系统数据库中检索的新冠肺炎疫苗不良反应被动监测数据。从最近报告的200例病例中提取并评估了检索到的人口统计信息记录以及10大常见疫苗不良事件,用于研究分析。结果本研究报告了局部和全身不良反应。前10种全身反应按年龄组(0.041)和性别(0.002)记录有显著差异(p<0.05)。对前5种全身反应的分析,按疫苗类型分层,得出寒战的显著差异(p=0.044),按年龄组和接种疫苗类型分层时,总的来说,辉瑞公司有182人(91.0%)报告不良事件,莫德纳公司有13人(6.5%),杨森公司有5人(2.5%)报告不良反应。因此,建议对所有不良事件进行持续监测和报告,以确保疫苗接种的安全性。
{"title":"Reactogenicity to COVID-19 vaccination in the United States of America","authors":"A. Sanyaolu, A. Marinkovic, S. Prakash, P. Desai, N. Haider, A. Abbasi, Nasima Mehraban, Isha Jain, Amarachi Ekeh, Omar Shazley, C. Okorie, V. Orish","doi":"10.7774/cevr.2022.11.1.104","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.104","url":null,"abstract":"Purpose In the United States, Pfizer-BioNTech, Moderna, and Janssen’s coronavirus disease 2019 (COVID-19) vaccines have been granted Emergency Use Authorization (EUA) with the Pfizer-BioNTech vaccine presently approved by the US Food and Drug Administration. The purpose of this study is to analyze passive surveillance data on COVID-19 vaccine adverse reaction in the United States. Materials and Methods We analyzed passive surveillance data on COVID-19 vaccine adverse reactions which were retrieved from the Vaccine Adverse Event Reporting System database. Retrieved records on demographic information as well as the top 10 common vaccine adverse events were extracted and assessed from 200 of the most recently reported cases for the study analysis. Results Local and systemic adverse reactions were reported in the study. A significant difference (p<0.05) was recorded for the top 10 systemic reactions by age category (0.041) and by gender (0.002). Analysis of the top five systemic reactions, stratified by vaccine type yielded a significant difference (p<0.05) for chills (p=0.044), and when stratified by age group and type of vaccination received, it yielded a significant difference (p<0.05) for fatigue (p=0.023). Overall, Pfizer had 182 persons (91.0%) reporting adverse events, Moderna with 13 (6.5%), and Janssen with 5 (2.5%). Conclusion Mild side effects were reported following vaccination with the EUA COVID-19 vaccines in the United States. Thus, continuous monitoring and reporting of all adverse events are recommended to ensure the safety of vaccination.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"104 - 115"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43802973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Alopecia areata after COVID-19 vaccination 接种新冠肺炎疫苗后的斑秃
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.129
G. Gallo, L. Mastorino, L. Tonella, S. Ribero, P. Quaglino
The coronavirus disease 2019 (COVID-19) vaccines are authorized for use in numerous countries worldwide. Several cutaneous findings are reported after severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccination. Here, we report the case of a patient with a rapid onset of alopecia areata immediately after receiving the second dose of the COVID-19 vaccine. Alopecia areata is a common autoimmune disease leading to non-scarring hair loss. Among the many cutaneous adverse effects reported after the anti-SARS-COV2 vaccination, no episodes of alopecia areata have been described to date. In this paper, we report the first case of alopecia areata after COVID-19 vaccination described in the literature with a revision of cases of alopecia areata reported after other types of vaccination. Although the significance of these skin reactions is not yet known, further studies will certainly clarify whether the development of alopecia areata or other forms of immune-mediated reactions could represent a positive prognostic factor regarding immune protection from SARS-CoV-2.
2019冠状病毒病(COVID-19)疫苗已被授权在全球许多国家使用。严重急性呼吸综合征冠状病毒2 (SARS-COV-2)疫苗接种后,报告了几种皮肤检查结果。在这里,我们报告了一例患者在接受第二剂COVID-19疫苗后立即出现快速发作的斑秃。斑秃是一种常见的自身免疫性疾病,导致无疤痕性脱发。在抗sars - cov2疫苗接种后报告的许多皮肤不良反应中,迄今尚未报告斑秃发作。在本文中,我们报道了文献中报道的第一例COVID-19疫苗接种后的斑秃病例,并对其他类型疫苗接种后的斑秃病例进行了修订。虽然这些皮肤反应的意义尚不清楚,但进一步的研究肯定会澄清斑秃或其他形式的免疫介导反应的发展是否可能代表对SARS-CoV-2免疫保护的积极预后因素。
{"title":"Alopecia areata after COVID-19 vaccination","authors":"G. Gallo, L. Mastorino, L. Tonella, S. Ribero, P. Quaglino","doi":"10.7774/cevr.2022.11.1.129","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.129","url":null,"abstract":"The coronavirus disease 2019 (COVID-19) vaccines are authorized for use in numerous countries worldwide. Several cutaneous findings are reported after severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccination. Here, we report the case of a patient with a rapid onset of alopecia areata immediately after receiving the second dose of the COVID-19 vaccine. Alopecia areata is a common autoimmune disease leading to non-scarring hair loss. Among the many cutaneous adverse effects reported after the anti-SARS-COV2 vaccination, no episodes of alopecia areata have been described to date. In this paper, we report the first case of alopecia areata after COVID-19 vaccination described in the literature with a revision of cases of alopecia areata reported after other types of vaccination. Although the significance of these skin reactions is not yet known, further studies will certainly clarify whether the development of alopecia areata or other forms of immune-mediated reactions could represent a positive prognostic factor regarding immune protection from SARS-CoV-2.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"129 - 132"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42708568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
期刊
Clinical and Experimental Vaccine Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1